Brain Trials
Subscribe
Sign in
Home
Notes
Archive
About
Sarepta’s DMD Elevidys Roller-Coaster: From Questionable Efficacy to Safety Alarms
What’s unraveling in the Duchenne muscular dystrophy (DMD) gene-therapy saga, and what it means for the future of AAV therapies
READ THE LATEST
Most Popular
View all
TREM2: A Promising but Elusive Target in Neurodegeneration
Dec 13, 2024
•
Jose-Alberto Palma MD PhD
7
Alpha-Synuclein: Recent Trials and Errors in Parkinson’s Disease
Jan 1
•
Jose-Alberto Palma MD PhD
2
2
Is Most Neurodegenerative Research Based on Fraudulent Data?
Jan 10
•
Jose-Alberto Palma MD PhD
4
The Rise and Fall of Cassava Sciences
Nov 29, 2024
•
Jose-Alberto Palma MD PhD
4
Latest
Top
Discussions
GLP-1 Receptor Agonists for Parkinson’s Disease: Promise or Mirage?
The recent failure of the Exenatide-PD3 trial forces a reevaluation of incretin-based therapies in Parkinson’s disease. Are these drugs still promising…
Apr 11
•
Jose-Alberto Palma MD PhD
2
The Billionaire Bet on Longevity Drug Development: Can Science Deliver?
From high-end biohacking clinics to billion-dollar biotech moonshots, the race to slow aging is booming. But with aging not classified as a disease, can…
Feb 8
•
Jose-Alberto Palma MD PhD
1
Two New Alzheimer's Definitions, One Big Debate: Are We Diagnosing Disease or Predicting Risk?
Two novel and competing criteria, one prioritizing biomarkers, the other integrating clinical symptoms, are reshaping how we diagnose Alzheimer’s…
Jan 18
•
Jose-Alberto Palma MD PhD
1
2
Is Most Neurodegenerative Research Based on Fraudulent Data?
The recent Masliah scandal and other fraud revelations force the neurodegeneration field to confront a chilling question: how much of its foundation is…
Jan 10
•
Jose-Alberto Palma MD PhD
4
Alpha-Synuclein: Recent Trials and Errors in Parkinson’s Disease
Recent setbacks in alpha-synuclein therapies, Roche's PADOVA and UCB/Novartis's ORCHESTRA, raise pressing questions: what’s next for disease-modifying…
Jan 1
•
Jose-Alberto Palma MD PhD
2
2
Brain Trials Christmas Special: NeuroScience Fiction
Exploring the intersection of imagination and neuroscience: a holiday deep dive into brain-inspired science fiction
Dec 20, 2024
•
Jose-Alberto Palma MD PhD
TREM2: A Promising but Elusive Target in Neurodegeneration
Alector’s anti-TREM2 antibody just failed in an Alzheimer’s Phase 2 trial, while Novartis bets big on their TREM2 antibody (VHB937) for ALS and…
Dec 13, 2024
•
Jose-Alberto Palma MD PhD
7
See all
Brain Trials
A deep dive into neuroscience drug development and clinical trials with comprehensive, accessible analysis and actionable insights.
Subscribe
Brain Trials
Subscribe
About
Archive
Sitemap
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts